$IKT

$1.52 -$0.07 (4.4%) Close

$IKT Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Ownership

13F as of Q2 2026 · 139.5M shares outstanding

Who owns IKT?

By type of holder

Institutions 84.5% Insiders 15.5% Everyone else 0.1%

Concentration Top 10 holders own 56.5%

Sands Capital Alternatives, LLC 9.3% · Soleus Capital Management, L.P. 7.8%

Institutional ownership

84.5%

+2.8 pts vs last qtr

Institutional holders

104

0 vs last qtr

Net shares bought

+3.8M

by institutions in Q2 2026

New / sold out

18 / 18

positions opened vs closed

How is ownership changing?

Institutions, last 8 quarters

Biggest buyers in Q2 2026

BlackRock, Inc. +1.5M
Kalehua Capital Management LLC +1.1M

Biggest sellers in Q2 2026

Perceptive Advisors LLC SOLD OUT −2.3M
Ally Bridge Group (NY) LLC SOLD OUT −1.3M

Who is planning to sell?

No insider has filed a notice of proposed sale (Form 144) for Inhibikase Therapeutics, Inc. in the last 12 months.

Is your stake being diluted?

Diluted share count, FY2024–FY2025

+314.6%

+314.60% a year

Each share's claim on the business

−75.9%

shrank without buying or selling a share

Spent on buybacks vs paid in stock

— vs $23.5M

over 2 fiscal years

Diluted shares, split-adjusted

Buybacks Stock-based comp

How patient are the owners?

Institutional shares by how long they've been held

5+ years0% 3–5 years10% 1–3 years55% Under 1 year35%

Quarterly turnover

7.5%

of institutional shares changed hands

Top 10 managers, median time held

1.5 years

Super Investors

Investment managers reporting IKT on Form 13F

Holder	Shares	% of company	Change vs last qtr	Held since	% of their book
SC Sands Capital Alternatives, LLC	13.0M	9.33%	Unchanged	2024	4.3%
Shares held by quarter Peak holding13.0M (Q4'25) Change over 8 quarters+13.0M Share of the company9.330% Sands Capital Alternatives, LLC's full portfolio →
SC Soleus Capital Management, L.P.	10.9M	7.79%	Unchanged	2024	0.8%
Shares held by quarter Peak holding10.9M (Q4'25) Change over 8 quarters+10.9M Share of the company7.790% Soleus Capital Management, L.P.'s full portfolio →

Sands Capital Alternatives, LLC

13.0M

% of company

9.33%

Change vs last qtr

Unchanged

Held since

2024

Soleus Capital Management, L.P.

10.9M

% of company

7.79%

Change vs last qtr

Unchanged

Held since

2024

28 more super investors behind a free account

See every manager holding Inhibikase Therapeutics, Inc., how their position has changed, and how long they've held it.

Institutional Funds

Mutual funds and ETFs reporting IKT on Form N-PORT; together they hold 10.5% of the company

Fund	Position value	Shares	% of company	% of the fund	As of
VT Vanguard Total Stock Market Index Fund Vanguard Index Funds	$7.64M	3.8M	2.70%	0.00%	June 30, 2026
IR iShares Russell 2000 ETF iShares Trust	$6.11M	3.0M	2.16%	0.01%	June 30, 2026

Vanguard Total Stock Market Index Fund

Vanguard Index Funds

Position value

$7.64M

% of company

2.70%

% of the fund

0.00%

As of

June 30, 2026

iShares Russell 2000 ETF

iShares Trust

Position value

$6.11M

% of company

2.16%

% of the fund

0.01%

As of

June 30, 2026

23 more funds behind a free account

See every fund holding Inhibikase Therapeutics, Inc. and how much of the fund the position is.

Insiders and 5%+ holders

From Forms 3/4/5 and Schedules 13D/G

Holder	Shares	% of company	Change vs last qtr	8 quarters	Held since	% of their book
CC Cabell Christopher Insider	676.6K	0.48%	—	—	—	—
Insider holdings come from Form 3/4/5 filings, which are not quarterly. Share of the company0.480% Cabell Christopher's insider activity →
VA Vincent Aurentz Insider	510.6K	0.37%	—	—	—	—
Insider holdings come from Form 3/4/5 filings, which are not quarterly. Share of the company0.370% Vincent Aurentz's insider activity →

Cabell Christopher

Insider

676.6K

% of company

0.48%

Change vs last qtr

—

Held since

—

Vincent Aurentz

Insider

510.6K

% of company

0.37%

Change vs last qtr

—

Held since

—

3 more holders behind a free account

See every insider and 5%+ holder of Inhibikase Therapeutics, Inc..

Comments